Eric Rose Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1701 N Main St, Beaver Dam, KY 42320 Phone: 270-274-4464 |
Dr. Michael Foster Desmond, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 500 N Main St, Beaver Dam, KY 42320 Phone: 270-274-9224 Fax: 270-274-9226 |
Mrs. Leslie Ellen Sampley, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1209 N Main St, Beaver Dam, KY 42320 Phone: 270-274-3318 |
Tamara Rhea Goff, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1209 N Main St, Beaver Dam, KY 42320 Phone: 270-274-3318 |
Dr. Brian Mayes, PHARM.D, BCACP Pharmacist - Ambulatory Care Medicare: Not Enrolled in Medicare Practice Location: 1209 N Main St, Beaver Dam, KY 42320 Phone: 270-274-3318 |
Meredith Figg, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1209 N Main St., Beaver Dam, KY 42320 Phone: 270-274-3318 |
News Archive
Exercise and physical activity should be considered as therapeutic options for lung cancer as they have been shown to reduce symptoms, increase exercise tolerance, improve quality of life, and potentially reduce length of hospital stay and complications following surgery for lung cancer.
A clinical study - known as IRONMAN - will determine if iron supplement injections could ease the disabling symptoms of heart failure. The trial was officially launched today at the British Cardiovascular Society Conference in Manchester.
Basic research into the dual nature of certain immune system cells has set the stage for a new approach to cancer immunotherapy that avoids some of the shortcomings associated with other methods, scientists at Dana-Farber Cancer Institute report in a new study in the Proceedings of the National Academy of Sciences.
The study, led by Dr. Shiela Strauss, Associate Professor of Nursing and Co-Director of the Statistics and Data Management Core for NYU's Colleges of Dentistry and Nursing, examined data from 2,923 adult participants in the 2003-2004 National Health and Nutrition Examination Survey who had not been diagnosed with diabetes.
DiosCURE SE announced a publication in Science describing its core technology of multivalent single-chain antibodies with a unique molecular mode-of-action to inactivate SARS-CoV-2 virions. An international team led by scientists at the University of Bonn developed and characterized the lead candidates, which are exclusively licensed by DiosCURE.
› Verified 3 days ago